目的系统分析大肠癌术后患者行化疗联合中药治疗的有效性、安全性。方法在PubMed、EMBASE、中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、维普中文科技期刊数据库、万方数据库中检索2004年1月-2014年4月关于大肠癌术后患者行化疗联合中药治疗的随机对照试验文献,并用RevMan 5.2进行统计分析。结果共纳入11篇相关文献,859例患者,试验组450例,对照组409例。结果显示：试验组不良反应发生率明显低于对照组（OR=0.32,95%CI：0.25-0.41,P〈0.000 01）;免疫功能及生命质量均较对照组明显提高,差异均有统计学意义（MD=0.91,95%CI：0.75-1.06,P〈0.000 01;MD=10.11,95%CI：5.95-14.28,P〈0.000 01）。结论大肠癌术后患者行化疗联合中药治疗不仅能改善生命质量,而且能降低不良反应,安全性较高。
Objective To analyze the effect and security of chemotherapy combined with traditional Chinese medicine in postoperative patients with colorectal cancer systematically. Methods The Pub Med, EMBASE, CBM, CNKI, VIP and Wanfang Data were searched for the randomized controlled trials of chemotherapy combined with traditional Chinese medicine in postoperative patients with colorectal cancer from January 2004 to April 2014, and Rev Man 5.2 was used for data analysis. Results 11 articles were eventually brought into the randomized controlled trial, a total of 859 patients. Among them, 450 cases were in the treatment group and 409 cases were in the control group. According to the Meta analysis： the incidence rate of adverse reactions in the treatment group was lower than that of control group（OR =0.32, 95%CI： 0.25-0.41, P〈 0.000 01）; the immunologic function and quality of life were significantly improved compared to the control group, the differences were statistically significant（OR = 0.91, 95%CI： 0.75-1.06, P 〈0.000 01;OR = 10.11, 95% CI： 5.95-14.28, P 〈0.000 01）. Conclusion Chemotherapy combined with traditional Chinese medicine not only can improve the quality of life and immunologic function, but also reduce adverse reactions and has a higher security.
China Medical Herald
Traditional Chinese medicine treatment
Randomized controlled trials